Log in

Relevant bibliographies by topics / Liquid biopsy / Journal articles

To see the other types of publications on this topic, follow the link: Liquid biopsy.

Journal articles on the topic 'Liquid biopsy'

Author: Grafiati

Published: 4 June 2021

Last updated: 7 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Liquid biopsy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Singh, Pratibha, Meenakshi Gothwal, and Garima Yadav. "Liquid Biopsy in Ovarian Cancer." Indian Journal of Obstetrics and Gynecology 6, no. 4 (2018): 427–31. http://dx.doi.org/10.21088/ijog.2321.1636.6418.16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Jain, Amit Kumar, Guruprasad Bhat, Vineet Govinda Gupta, and Hari Goyal. "Liquid Biopsy." Indian Journal of Medical and Paediatric Oncology 42, no. 01 (March 2021): 077–79. http://dx.doi.org/10.1055/s-0041-1729434.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Goodwin, Peter M. "Liquid Biopsy." Oncology Times 38, no. 13 (July 2016): 40. http://dx.doi.org/10.1097/01.cot.0000489521.34002.61.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Siddiqua, Umme Iffat. "Liquid Biopsy." KYAMC Journal 10, no. 1 (May 22, 2019): 1. http://dx.doi.org/10.3329/kyamcj.v10i1.41473.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Gingras, Isabelle, Roberto Salgado, and Michail Ignatiadis. "Liquid biopsy." Current Opinion in Oncology 27, no. 6 (November 2015): 560–67. http://dx.doi.org/10.1097/cco.0000000000000223.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lavine, M. S. "Liquid Biopsy." Science 328, no. 5975 (April 8, 2010): 141. http://dx.doi.org/10.1126/science.328.5975.141-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hekmat, K., and C. Bruns. "„Liquid biopsy“." Der Chirurg 90, S2 (February 13, 2019): 120. http://dx.doi.org/10.1007/s00104-019-0845-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Hekmat, K., and C. Bruns. "„Liquid biopsy“." Der Chirurg 88, no. 7 (June 14, 2017): 621. http://dx.doi.org/10.1007/s00104-017-0458-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Fulmer, Tim. "Liquid biopsy." Science-Business eXchange 5, no. 26 (June 2012): 668. http://dx.doi.org/10.1038/scibx.2012.668.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Imyanitov, E. N., E. Sh Kuligina, and G. A. Janus. "LIQUID BIOPSY IN CLINICAL ONCOLOGY." Practical oncology 23, no. 4 (December 30, 2022): 211–24. http://dx.doi.org/10.31917/2304211.

Full text

Abstract:

Liquid biopsy is the analysis of tumor fragments (entire cells, nucleic acids,proteins) in hysiological and pathological body liquids. This technology has already been included in standard procedures of detecting secondary mutations, which are associate with acquired drug resistance. Liquid biopsy is a promising tool for early cancer detection, evaluation of the success of radical cancer surgery, monitoring of residual tumor disease, assessment of treatment efficacy etc.

APA, Harvard, Vancouver, ISO, and other styles

11

Ranuncolo, Stella Maris. "Liquid Biopsy in Liquid Tumors." Journal of Cancer Therapy 08, no. 03 (2017): 302–20. http://dx.doi.org/10.4236/jct.2017.83026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

R, Dr Kalyani. "Liquid Biopsy : An emerging concept for diagnosis and management of cancer." JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 09, no. 4 (December 15, 2019): 91–96. http://dx.doi.org/10.58739/jcbs/v09i4.4.

Full text

Abstract:

Tumour diagnosis is conventionally done by radiological findings and invasive surgical biopsy. Of late non-invasive technique where blood sample, urine and body fluids are used to extract circulating tumour cells (CTC) and genetic material for cancer diagnosis and treatment which is called as “Liquid Biopsy”.1,2 In this technique the liquid sample is used to isolate CTC, circulating tumour DNA (ctDNA), RNA, Exosomes and proteins which are shed by tumour cells into blood circulation, body fluids or urine in most of the cancers depending on the site of the can-cer. This technique enables non-invasive profiling of solid tumours, the results which can be comparable with that of tissue biopsy.3,4,5,6,7 As tissue biopsy is single biopsy, it gives only spatially and temporary snap shot of genetic makeup of cancer tissue unlike liquid biopsy, where samples can be taken at repeated intervals and it reveals the dynamic and heterogenei-ty of the cancer tissue.[8] Originally liquid biopsy was used to analyze CTC. At present it mainly analyzes ctDNA. However CTC and ctDNA are complementary technologies which can be used in parallel. As ctDNA is a potential surrogate for the entire tumour genome, it is many times referred as “Liquid Biopsy”.9,10 The different components of liquid biopsy are CTC, ctDNA, RNA, Exosomes, Proteins and Platelets.

APA, Harvard, Vancouver, ISO, and other styles

13

Trombetta, Domenico, Angelo Sparaneo, Federico Pio Fabrizio, and Lucia Anna Muscarella. "Liquid biopsy and NSCLC." Lung Cancer Management 5, no. 2 (June 2016): 91–104. http://dx.doi.org/10.2217/lmt-2016-0006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Ronvaux, Lorian, Matteo Riva, An Coosemans, Marielle Herzog, Guillaume Rommelaere, Nathalie Donis, Lionel D’Hondt, and Jonathan Douxfils. "Liquid Biopsy in Glioblastoma." Cancers 14, no. 14 (July 13, 2022): 3394. http://dx.doi.org/10.3390/cancers14143394.

Full text

Abstract:

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.

APA, Harvard, Vancouver, ISO, and other styles

15

Banys-Paluchowski, Maggie, Natalia Krawczyk, and Tanja Fehm. "Liquid Biopsy beim Mammakarzinom." Senologie - Zeitschrift für Mammadiagnostik und -therapie 18, no. 04 (December 2021): 365–76. http://dx.doi.org/10.1055/a-1678-1129.

Full text

Abstract:

ZusammenfassungIn den letzten Jahren gewinnt die Liquid Biopsy, d. h. die blutbasierte Untersuchung von zirkulierenden Tumorzellen (CTCs) und Nukleinsäuren (DNA/RNA) beim Mammakarzinom zunehmend an Relevanz. Zahlreiche Studien haben bereits die hohe prognostische Bedeutung der CTC-Detektion sowohl im frühen als auch metastasierten Stadium gezeigt. Des Weiteren korrelieren die Veränderungen der CTC-Zahlen und der zirkulierenden Tumor-DNA (ctDNA) im Verlauf der Erkrankung mit dem Ansprechen auf die Therapie. Im Fokus der Forschung stehen derzeit die Liquid-Biopsy-basierten Therapieinterventionen beim metastasierten Mammakarzinom. In diesem Kontext wurde Alpelisib, ein PI3K-Inhibitor, als erste Substanz durch die FDA und die EMA zugelassen.

APA, Harvard, Vancouver, ISO, and other styles

16

Banys-Paluchowski, Maggie, Natalia Krawczyk, and Tanja Fehm. "Liquid Biopsy beim Mammakarzinom." TumorDiagnostik & Therapie 42, no. 05 (May 31, 2021): 361–72. http://dx.doi.org/10.1055/a-1467-0165.

Full text

Abstract:

ZusammenfassungIn den letzten Jahren gewinnt die Liquid Biopsy, d. h. die blutbasierte Untersuchung von zirkulierenden Tumorzellen (CTCs) und Nukleinsäuren (DNA/RNA) beim Mammakarzinom zunehmend an Relevanz. Zahlreiche Studien haben bereits die hohe prognostische Bedeutung der CTC-Detektion sowohl im frühen als auch metastasierten Stadium gezeigt. Des Weiteren korrelieren die Veränderungen der CTC-Zahlen und der zirkulierenden Tumor-DNA (ctDNA) im Verlauf der Erkrankung mit dem Ansprechen auf die Therapie. Im Fokus der Forschung stehen derzeit die Liquid-Biopsy-basierten Therapieinterventionen beim metastasierten Mammakarzinom. In diesem Kontext wurde Alpelisib, ein PI3K-Inhibitor, als erste Substanz durch die FDA und die EMA zugelassen.

APA, Harvard, Vancouver, ISO, and other styles

17

Rossi, Davide, Valeria Spina, Alessio Bruscaggin, and Gianluca Gaidano. "Liquid biopsy in lymphoma." Haematologica 104, no. 4 (March 7, 2019): 648–52. http://dx.doi.org/10.3324/haematol.2018.206177.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Poulet, Geoffroy, Joséphine Massias, and Valerie Taly. "Liquid Biopsy: General Concepts." Acta Cytologica 63, no. 6 (2019): 449–55. http://dx.doi.org/10.1159/000499337.

Full text

Abstract:

Liquid biopsy provides the opportunity of detecting, analyzing and monitoring cancer in various body effluents such as blood or urine instead of a fragment of cancer tissue. It is composed of different biological matrices such as circulating tumor cells (CTCs), cell free nucleic acids, exosomes or tumors “educated platelets.” In addition to representing a non- or minimally invasive procedure, it should represent a better view of tumor heterogeneity and allows for real-time monitoring of cancer evolution. Recent technological and molecular advances, greatly facilitated by the use of microfluidics in many cases, have permitted large progresses both in our ability to purify and analyze liquid biopsy components. In particular, the great developments of droplet-based digital PCR and the various optimizations of next generation sequencing technologies are central to the several validations of CTC-free DNA as a strong cancer biomarker. However, complete adoption of liquid biopsy in clinics will require pursuing recent efforts in the standardization of procedures both on the pre-analytical and analytical aspects.

APA, Harvard, Vancouver, ISO, and other styles

19

Wu, Lingling, Yidi Wang, Lin Zhu, Yilong Liu, Teng Wang, Dan Liu, Yanling Song, and Chaoyong Yang. "Aptamer-Based Liquid Biopsy." ACS Applied Bio Materials 3, no. 5 (February 11, 2020): 2743–64. http://dx.doi.org/10.1021/acsabm.9b01194.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Wakelee, H. "PC 03.03 Liquid Biopsy." Journal of Thoracic Oncology 12, no. 11 (November 2017): S1666—S1667. http://dx.doi.org/10.1016/j.jtho.2017.09.197.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Salinas-Sánchez, A. S., C. Martínez-Sanchís, J. M. Giménez-Bachs, and D. C. García-Olmo. "Liquid biopsy in cancer." Actas Urológicas Españolas (English Edition) 40, no. 1 (January 2016): 1–2. http://dx.doi.org/10.1016/j.acuroe.2015.11.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Stone, Louise. "Biomarkers from liquid biopsy." Nature Reviews Urology 13, no. 8 (July 19, 2016): 434. http://dx.doi.org/10.1038/nrurol.2016.133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Behrend, Christian. "Liquid Biopsy beim Kolonkarzinom." Im Focus Onkologie 21, no. 3 (March 2018): 15–16. http://dx.doi.org/10.1007/s15015-018-3816-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

red. "Therapiekontrolle durch Liquid Biopsy." Info Onkologie 19, no. 8 (December 2016): 37. http://dx.doi.org/10.1007/s15004-016-5528-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Reimers, Natalie, Claudia Hille, and Klaus Pantel. "Aktuelles zur Liquid Biopsy." InFo Onkologie 21, S1 (June 2018): 24–29. http://dx.doi.org/10.1007/s15004-018-6134-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Harbour, J. William. "Liquid Biopsy in Retinoblastoma." JAMA Ophthalmology 135, no. 11 (November 1, 2017): 1231. http://dx.doi.org/10.1001/jamaophthalmol.2017.4094.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Voelker, Rebecca. "Liquid Biopsy Receives Approval." JAMA 316, no. 3 (July 19, 2016): 260. http://dx.doi.org/10.1001/jama.2016.8833.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Eibl, Robert H., and Markus Schneemann. "Liquid biopsy and glioblastoma." Exploration of Targeted Anti-tumor Therapy 4, no. 1 (February 26, 2023): 28–41. http://dx.doi.org/10.37349/etat.2023.00121.

Full text

Abstract:

Glioblastoma is the most common and malignant primary brain tumor. Despite a century of research efforts, the survival of patients has not significantly improved. Currently, diagnosis is based on neuroimaging techniques followed by histopathological and molecular analysis of resected or biopsied tissue. A recent paradigm shift in diagnostics ranks the molecular analysis of tissue samples as the new gold standard over classical histopathology, thus correlating better with the biological behavior of glioblastoma and clinical prediction, especially when a tumor lacks the typical hallmarks for glioblastoma. Liquid biopsy aims to detect and quantify tumor-derived content, such as nucleic acids (DNA/RNA), circulating tumor cells (CTCs), or extracellular vesicles (EVs) in biofluids, mainly blood, cerebrospinal fluid (CSF), or urine. Liquid biopsy has the potential to overcome the limitations of both neuroimaging and tissue-based methods to identify early recurrence and to differentiate tumor progression from pseudoprogression, without the risks of repeated surgical biopsies. This review highlights the origins and time-frame of liquid biopsy in glioblastoma and points to recent developments, limitations, and challenges of adding liquid biopsy to support the clinical management of glioblastoma patients.

APA, Harvard, Vancouver, ISO, and other styles

29

Ilié, Marius, and Paul Hofman. "Pros: Can tissue biopsy be replaced by liquid biopsy?" Translational Lung Cancer Research 5, no. 4 (August 2016): 420–23. http://dx.doi.org/10.21037/tlcr.2016.08.06.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Corcoran, Ryan B. "Liquid biopsy versus tumor biopsy for clinical-trial recruitment." Nature Medicine 26, no. 12 (November 23, 2020): 1815–16. http://dx.doi.org/10.1038/s41591-020-01169-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Saini, Aman, Yash Pershad, Hassan Albadawi, Malia Kuo, Sadeer Alzubaidi, Sailendra Naidu, M.-Grace Knuttinen, and Rahmi Oklu. "Liquid Biopsy in Gastrointestinal Cancers." Diagnostics 8, no. 4 (October 29, 2018): 75. http://dx.doi.org/10.3390/diagnostics8040075.

Full text

Abstract:

Liquid biopsy is the sampling of any biological fluid in an effort to enrich and analyze a tumor’s genetic material. Peripheral blood remains the most studied liquid biopsy material, with circulating tumor cells (CTC’s) and circulating tumor DNA (ctDNA) allowing the examination and longitudinal monitoring of a tumors genetic landscape. With applications in cancer screening, prognostic stratification, therapy selection and disease surveillance, liquid biopsy represents an exciting new paradigm in the field of cancer diagnostics and offers a less invasive and more comprehensive alternative to conventional tissue biopsy. Here, we examine liquid biopsies in gastrointestinal cancers, specifically colorectal, gastric, and pancreatic cancers, with an emphasis on applications in diagnostics, prognostics and therapeutics.

APA, Harvard, Vancouver, ISO, and other styles

32

Cheung, Alvin Ho-Kwan, Chit Chow, and Ka-Fai To. "Latest development of liquid biopsy." Journal of Thoracic Disease 10, S14 (June 2018): S1645—S1651. http://dx.doi.org/10.21037/jtd.2018.04.68.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Stickeler, Elmar. "Urindiagnostik – die neue Liquid Biopsy." Der Gynäkologe 54, no. 3 (February 4, 2021): 175–80. http://dx.doi.org/10.1007/s00129-021-04749-w.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Zmarzły, Nikola, Ewelina Hermyt, Andrzej Witek, Joanna Gola, and Urszula Mazurek. "Liquid biopsy in endometrial cancer." Current Gynecologic Oncology 17, no. 1 (July 31, 2019): 27–42. http://dx.doi.org/10.15557/cgo.2019.0004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

AKIN KABALAK, Pinar, and Ulku YILMAZ. "Liquid Biopsy in Lung Cancer." Güncel Göğüs Hastalıkları Serisi 6, no. 3 (August 4, 2020): 18–22. http://dx.doi.org/10.5152/gghs.2018.036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Eibl, Robert H., and Markus Schneemann. "Liquid biopsy for monitoring medulloblastoma." Extracellular Vesicles and Circulating Nucleic Acids 3, no. 3 (2022): 263–74. http://dx.doi.org/10.20517/evcna.2022.36.

Full text

Abstract:

Despite recent progress in molecular diagnostics defining four distinct medulloblastoma groups, the clinical management of these malignant childhood tumors of the cerebellum remains challenging. After surgical removal of the tumor, both cytotoxic chemotherapy and irradiation can offer additional curative benefits, but they also include a significant risk of long-term damage. Early molecular profiling aims to predict the outcome of such aggressive therapies. This prevents unnecessary damage to patients who may not need it and helps to identify those patients with remaining tumor cells who may benefit from more aggressive treatment with the intent to cure. Monitoring tumor evolution in real time allows personalized precision medicine with an immediate clinical response resulting in a better outcome. Liquid biopsy includes various methodologies already applied in numerous studies and clinical trials for common cancers including brain tumors, but information on medulloblastomas is limited. This review summarizes the recent developments of how liquid biopsy can support or even replace the standard monitoring of medulloblastomas by medical imaging or cytology and discusses what will be needed to make liquid biopsy a new gold standard in diagnosis, therapy, and follow-up of medulloblastomas for the benefit of the patients.

APA, Harvard, Vancouver, ISO, and other styles

37

Sahoo, TapanKumar. "Liquid biopsy in oncology practice." Oncology Journal of India 2, no. 3 (2018): 45. http://dx.doi.org/10.4103/oji.oji_32_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Ranade, A. A., A. Bhatt, Darshana Patil, Indu Patwal, D. B. Akolkar, D. A. Joshi, P. P. Patil, R. R. Dasare, T. D. Bhangale, and Y. R. Jha. "Liquid biopsy in periampullary carcinoma." International Journal of Molecular and Immuno Oncology 1, no. 1 (November 25, 2016): 45. http://dx.doi.org/10.18203/issn.2456-3994.intjmolimmunooncol20164388.

Full text

Abstract:

<p style="margin: 0in 0in 8pt 0.25in; text-align: justify;">Periampullary cancers are rare tumors arising within 2 cm of the major papilla of the duodenum. In this case report, we describe the use of liquid biopsy to analyze cell-free tumor DNA and exosomal microRNA to guide treatment selection in a patient with periampullary adenocarcinoma. To our knowledge, this is the first time such case report has been described in the literature.</p>

APA, Harvard, Vancouver, ISO, and other styles

39

Pankaj, Sangeeta. "Liquid biopsy in ovarian carcinoma." Journal of Indira Gandhi Institute Of Medical Sciences 7, no. 2 (2021): 79. http://dx.doi.org/10.4103/jigims.jigims_47_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Mahdi, Ahmed. "LIQUID BIOPSY- A NEW PROSPECT." Iraqi Journal of Medical Sciences 16, no. 4 (December 31, 2018): 353–56. http://dx.doi.org/10.22578/ijms.16.4.1.

Full text

Abstract:

Tissue biopsy has been the mainstay in tumor diagnosis for centuries. But due to its invasiveness and the heterogeneity of tumors there was a need for an alternative or adjuvant techniques to diagnose and assess tumors. Liquid biopsy is emerging as a new technique that will open the way for the diagnosis, tumor characterization, assess disease prognosis and individualize treatment options in cancer patients. Keywords:Biopsy, CTC, ctDNA Citation: Mahdi AK. Liquid biopsy - A new prospect. Iraqi JMS. 2018; 16(4): 353-356. doi: 10.22578/IJMS.16.4.1

APA, Harvard, Vancouver, ISO, and other styles

41

Ueda, Koji. "Cancer liquid biopsy using exosomes." Electrophoresis Letters 61, no. 2 (2017): 65–68. http://dx.doi.org/10.2198/electroph.61.65.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Lousada-Fernandez, Fatima, Oscar Rapado-Gonzalez, Jose-Luis Lopez-Cedrun, Rafael Lopez-Lopez, Laura Muinelo-Romay, and Maria Suarez-Cunqueiro. "Liquid Biopsy in Oral Cancer." International Journal of Molecular Sciences 19, no. 6 (June 8, 2018): 1704. http://dx.doi.org/10.3390/ijms19061704.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Santise, G., D. Maselli, C. Mignogna, K. PIrrone, V. Mollace, G. Donato, and N. Malara. "RF41 LIQUID BIOPSY FORCARDIAC TUMORS." Journal of Cardiovascular Medicine 19 (November 2018): e77. http://dx.doi.org/10.2459/01.jcm.0000550086.27815.c2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Lissa, Delphine, and Ana I. Robles. "Methylation analyses in liquid biopsy." Translational Lung Cancer Research 5, no. 5 (October 2016): 492–504. http://dx.doi.org/10.21037/tlcr.2016.10.03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Holzhauer, Peter. "Liquid Biopsy – Diagnostik mit Januskopf?" Deutsche Zeitschrift für Onkologie 51, no. 02 (June 2019): 57. http://dx.doi.org/10.1055/a-0865-8451.

Full text

Abstract:

Die manchmal unfassbaren und grenzenlos anmutenden Einblicke in die molekulare Individualität eines jeden von uns wurden in den letzten Jahren durch rasante Fortschritte im Bereich innovativer molekulargenetischer Untersuchungsmethoden, wie Next Generation Sequencing möglich.

APA, Harvard, Vancouver, ISO, and other styles

46

Reddi, Honey. "Current Applications for Liquid Biopsy." Clinical OMICs 5, no. 1 (January 2018): 11. http://dx.doi.org/10.1089/clinomi.05.01.10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Zhang, Hui-Juan, Xin-Hui Fang, and Jian Li. "Liquid biopsy in colorectal cancer." World Chinese Journal of Digestology 26, no. 3 (January 28, 2018): 182–89. http://dx.doi.org/10.11569/wcjd.v26.i3.182.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Benka, Stephen G. "Macrophages in a liquid biopsy." Physics Today 67, no. 5 (May 2014): 16–17. http://dx.doi.org/10.1063/pt.3.2373.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Shankar, Ganesh M., Leonora Balaj, Shannon L. Stott, Brian Nahed, and Bob S. Carter. "Liquid biopsy for brain tumors." Expert Review of Molecular Diagnostics 17, no. 10 (September 6, 2017): 943–47. http://dx.doi.org/10.1080/14737159.2017.1374854.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Pisapia, Pasquale, Umberto Malapelle, and Giancarlo Troncone. "Liquid Biopsy and Lung Cancer." Acta Cytologica 63, no. 6 (December 19, 2018): 489–96. http://dx.doi.org/10.1159/000492710.

Full text

Abstract:

The identification of non-small cell lung cancer (NSCLC) patients potentially responsive to targeted therapies relies on a number of relevant biomarkers, including EGFR, ALK, ROS-1, and PD-L1. Biomarker identification is most commonly based on surgical sample collection. However, when tissues are difficult to reach or when multiple analyses are necessary to monitor tumor progression and treatment response, liquid biopsy is a valid noninvasive alternative. This analysis, which is preferentially performed on circulating tumor DNA (ctDNA) extracted from plasma samples, has the major advantage of reducing the inherent risks and discomfort of tissue biopsy. However, a major disadvantage is that it yields only a low number of ctDNA targets. Thus, to avoid false-positive and false-negative results, it is important to adopt and validate technologies with high sensitivity and specificity in the pre-analytical phase of sampling. This review succinctly addresses the principal methodologies for analyzing plasma-derived ctDNA in NSCLC patients.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!